Amifostine: is there evidence of tumor protection?

This publication has 68 references indexed in Scilit:

• Antimetastatic effectiveness of amifostine therapy following surgical removal of Sa-NH tumors in mice
  Seminars in Oncology, 2002
• Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity
  Seminars in Oncology, 2002
• The Effect of Amifostine on the in Vitro Cytotoxicity of Chemotherapeutic Agents in Three Epithelial Ovarian Carcinoma Cell Lines
  Gynecologic Oncology, 1999
• Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors
  Cancer, 1997
• WR-1065, the active metabolite of amifostine (ethyol®), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells
  European Journal Of Cancer, 1996
• Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancer
  Anti-Cancer Drugs, 1996
• Amifostine (WR-2721) Protects Normal Haematopoietic Stem Cells Against Cyclophosphamide Derivatives' Toxicity Without Compromising Their Antileukaemic Effects
  European Journal Of Cancer, 1995
• Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice
  European Journal Of Cancer, 1994
• Use of radiation with or without WR-2721 in advanced rectal cancer
  Cancer, 1992
• Effect of the Radioprotector WR 2721 on the Response of Metastatic Lewis Lung Carcinoma Colonies to Alkylating Agents
  Acta Radiologica: Oncology, 1985